S-ketamine and GABA-A-receptor interaction in humans: An exploratory study with I-123-iomazenil SPECT

Human Psychopharmacology

Volumn 23, Issue 7, 2008, Pages 549-554

  Heinzel, Alexander ^a,b   Steinke, Rainer ^a   Poeppel, Thorsten Dirk ^c   Grosser, Oliver ^a   Bogerts, Bernhard ^a   Otto, Hans ^a   Northoff, Georg ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

GABA A; I 123 iomazenil; Medial prefrontal cortex; S ketamine; SPECT

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; IOMAZENIL I 123; KETAMINE; PLACEBO; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BIOCHEMISTRY; BRAIN; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG INFUSION; FEMALE; HUMAN; HUMAN EXPERIMENT; HYDROCORTISONE BLOOD LEVEL; IMAGE ANALYSIS; IN VIVO STUDY; MALE; NEGATIVE SYNDROME; NORMAL HUMAN; PARAMETRIC TEST; POSITIVE SYNDROME; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BINDING; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; ANALYSIS OF VARIANCE; ANESTHETICS, DISSOCIATIVE; BRAIN MAPPING; BRIEF PSYCHIATRIC RATING SCALE; CASE-CONTROL STUDIES; CEREBRAL CORTEX; FEMALE; FLUMAZENIL; HUMANS; HYDROCORTISONE; IODINE RADIOISOTOPES; KETAMINE; MALE; PROLACTIN; RECEPTORS, GABA-A; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; YOUNG ADULT;

EID: 57149141413     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.960     Document Type: Article

References (30)

1. Bartenstein P, Ludolph A, Schober O, et al. 1991. Benzodiazepine receptors and cerebral blood flow in partial epilepsy. Eur J Nucl Med 18(2): 111-118.
2. Beer HF, Blauenstein PA, Hasler PH, et al. 1990. In vitro and in vivo evaluation of iodine-123-Ro 16-0154: a new imaging agent for SPECT investigations of benzodiazepine receptors. J Nucl Med 31: 1007-1014.
3. Gage PW, Robertson B. 1985. Prolongation of inhibitory postsynaptic currents by pentobarbitone, halothane and ketamine in CA1 pyramidal cells in rat hippocampus. Br J Pharmacol 85(3): 675-681.
4. Gouzoulis-Mayfrank E, Heekeren K, Neukirch A, et al. 2006. Inhibition of return in the human 5HT2A agonist and NMDA antagonist model of psychosis. Neuropsychopharmacology 31(2): 431-441.
5. Irifune M, Sato T, Kamata Y, Nishikawa T, Dohi T, Kawahara M. 2000. Evidence for GABA(A) receptor agonistic properties of ketamine: convulsive and anesthetic behavioral models in mice. Anesth Analg 91(1): 230-236.
6. Irifune M, Sato T, Kamata Y, et al. 1998. Inhibition by diazepam of ketamine-induced hyperlocomotion and dopamine turnover in mice. Can J Anaesth 45(5): 471-478.
7. Kugaya A, Sanacora G, Verhoeff NP, et al. 2003. Cerebral benzodiazepine receptors in depressed patients measured with [123I]iomazenil SPECT. Biol Psychiatry 54(8): 792-799.
8. Lahorte P, Vandenberghe S, Van LK, Audenaert K, Lemahieu I, Dierckx RA. 2000. Assessing the performance of SPM analyses of spect neuroactivation studies. Statistical parametric mapping. Neuroimage 12(6): 757-764.
9. Langsjo JW, Maksimow A, Salmi E, et al. 2005. S-ketamine anesthesia increases cerebral blood flow in excess of the metabolic needs in humans. Anesthesiology 103(2): 258-268.
10. Lassen NA. 1996. A reappraisal of the relative merits of SPET and PET in the quantitation of neuroreceptors: the advantage of a longer half-life! Eur J Nucl Med 23(1): 1-4.
11. Lin LH, Chen LL, Zirrolli JA, Harris RA. 1992. General anesthetics potentiate gamma-aminobutyric acid actions on gammaaminobutyric acid A receptors expressed by Xenopus oocytes: lack of involvement of intracellular calcium. J Pharmacol Exp Ther 263(2): 569-578.
12. Lipp M, Daublander M, Sebastian M, Dick W. 1995. Analgesiasedation for maxillo-facial surgery with midazolam-pentazocine and miazolam-ketamine. Clinical double-blind study of anxiety, analgesia, sedation and amnesia. Anaesthesist 44(8): 566-572.
13. Liske S, Li A, Morris ME. 1990. Effects of ketamine on GABA-evoked excitability of peripheral nerve. Exp Brain Res 79(1): 187-191.
14. Little HJ, Atkinson HD. 1984. Ketamine potentiates the responses of the rat superior cervical ganglion to GABA. Eur J Pharmacol 98(1): 53-59.
15. Matusch A, Hurlemann R, Rota KE, et al. 2007. Acute S-ketamine application does not alter cerebral [(18)F] altanserin binding: a pilot PET study in humans. J Neural Transm 114(11): 1433-1442.
16. Northoff G, Richter A, Bermpohl F, et al. 2005. NMDA hypofunction in the posterior cingulate as a model for schizophrenia: an exploratory ketamine administration study in fMRI. Schizophr Res 72(2-3): 235-248.
17. Overall JE, Gorham DR. 2007. The brief psychiatric rating scale. Psychol Rep 10: 799-812.
18. Passie T, Karst M, Borsutzky M, Wiese B, Emrich HM, Schneider U. 2003. Effects of different subanaesthetic doses of (S)-ketamine on psychopathology and binocular depth inversion in man. J Psychopharmacol 17(1): 51-56.
19. Restall J, Johnston IG, Robinson DN. 1990. Flumazenil in ketamine and midazolam anaesthesia. Anaesthesia 45(11): 938-940.
20. Restall J, Tully AM, Ward PJ, Kidd AG. 1988. Total intravenous anaesthesia for military surgery. A technique using ketamine, midazolam and vecuronium. Anaesthesia 43(1): 46-49.
21. Salmi E, Langsjo JW, Aalto S, et al. 2005. Subanesthetic ketamine does not affect 11C-flumazenil binding in humans. Anesth Analg 101(3): 722-725, table.
22. Scholfield CN. 1980. Potentiation of inhibition by general anaesthetics in neurones of the olfactory cortex in vitro. Pflugers Arch 383(3): 249-255.
23. Sonner JM, Zhang Y, Stabernack C, Abaigar W, Xing Y, Laster MJ. 2003. GABA(A) receptor blockade antagonizes the immobilizing action of propofol but not ketamine or isoflurane in a dose-related manner. Anesth Analg 96(3): 706-712 table.
24. Spielberger CD. 1980. Test Anxiety Inventory. Consulting Psychologist Press: Palo Alto, CA.
25. Spitzer RL, Williams JBW, Gibbon M, First MB. 1990. Structural Clinical Interview for DSM-III/R Non-Patient Edition (SCID-NP; Version 1.0). American Psychiatric Press: Washington.
26. Verhoeff NP, Soares JC, D'Souza CD, et al. 1999. [123I]Iomazenil SPECT benzodiazepine receptor imaging in schizophrenia. Psychiatry Res 91(3): 163-173.
27. Vollenweider FX, Geyer MA. 2001. A systems model of altered consciousness: integrating natural and drug-induced psychoses. Brain Res Bull 56(5): 495-507.
28. Vollenweider FX, Leenders KL, Oye I, Hell D, Angst J. 1997. Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). Eur Neuropsychopharmacol 7(1): 25-38.
29. Vollenweider FX, Vontobel P, Oye I, Hell D, Leenders KL. 2000. Effects of (S)-ketamine on striatal dopamine: a [11C]raclopride PET study of a model psychosis in humans. J Psychiatr Res 34(1): 35-43.
30. Zarate CA, Jr., Singh JB, Carlson PJ, et al. 2006. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63(8): 856-864.